249 related articles for article (PubMed ID: 12655347)
1. Hepatitis C and liver fibrosis.
Schuppan D; Krebs A; Bauer M; Hahn EG
Cell Death Differ; 2003 Jan; 10 Suppl 1():S59-67. PubMed ID: 12655347
[TBL] [Abstract][Full Text] [Related]
2. Host genetic factors influence disease progression in chronic hepatitis C.
Powell EE; Edwards-Smith CJ; Hay JL; Clouston AD; Crawford DH; Shorthouse C; Purdie DM; Jonsson JR
Hepatology; 2000 Apr; 31(4):828-33. PubMed ID: 10733535
[TBL] [Abstract][Full Text] [Related]
3. Cu-Zn super oxide dismutase as a potential antifibrotic drug for hepatitis C related fibrosis.
Emerit J; Samuel D; Pavio N
Biomed Pharmacother; 2006 Jan; 60(1):1-4. PubMed ID: 16297593
[TBL] [Abstract][Full Text] [Related]
4. Serum transforming growth factor-beta1(TGF-beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C [corrected].
Kirmaz C; Terzioglu E; Topalak O; Bayrak P; Yilmaz O; Ersoz G; Sebik F
Eur Cytokine Netw; 2004; 15(2):112-6. PubMed ID: 15319169
[TBL] [Abstract][Full Text] [Related]
5. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.
Ben-Ari Z; Pappo O; Druzd T; Sulkes J; Klein T; Samra Z; Gadba R; Tambur AR; Tur-Kaspa R; Mor E
Cytokine; 2004 Jul; 27(1):7-14. PubMed ID: 15207246
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats.
Arias M; Sauer-Lehnen S; Treptau J; Janoschek N; Theuerkauf I; Buettner R; Gressner AM; Weiskirchen R
BMC Gastroenterol; 2003 Oct; 3():29. PubMed ID: 14565855
[TBL] [Abstract][Full Text] [Related]
7. Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.
Xu W; Wang LW; Shi JZ; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):300-8. PubMed ID: 19502172
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription.
Taniguchi H; Kato N; Otsuka M; Goto T; Yoshida H; Shiratori Y; Omata M
J Med Virol; 2004 Jan; 72(1):52-9. PubMed ID: 14635011
[TBL] [Abstract][Full Text] [Related]
9. [Role of the Regulatory T lymphocytes in hepatitis C fibrosis progression].
Delhem N; Cottrez F; Carpentier A; Miroux C; Moralès O; François V; Groux H; Auriault C; Pancré V
Bull Cancer; 2008 Nov; 95(11):1029-38. PubMed ID: 19036674
[TBL] [Abstract][Full Text] [Related]
10. Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development.
Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Shirai Y; Yoshii J; Yanase K; Fukui H
Int J Mol Med; 2011 Jul; 28(1):81-8. PubMed ID: 21455560
[TBL] [Abstract][Full Text] [Related]
11. Extracts of Lindera obtusiloba induce antifibrotic effects in hepatic stellate cells via suppression of a TGF-beta-mediated profibrotic gene expression pattern.
Ruehl M; Erben U; Kim K; Freise C; Dagdelen T; Eisele S; Trowitzsch-Kienast W; Zeitz M; Jia J; Stickel F; Somasundaram R
J Nutr Biochem; 2009 Aug; 20(8):597-606. PubMed ID: 18824344
[TBL] [Abstract][Full Text] [Related]
12. New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection Induces Transforming Growth Factor β1 Production through Glucose-Regulated Protein 94.
Jee MH; Hong KY; Park JH; Lee JS; Kim HS; Lee SH; Jang SK
J Virol; 2015 Dec; 90(6):3044-55. PubMed ID: 26719248
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.
Friedman SL
Nat Clin Pract Gastroenterol Hepatol; 2004 Dec; 1(2):98-105. PubMed ID: 16265071
[TBL] [Abstract][Full Text] [Related]
14. Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets?
Schuppan D; Koda M; Bauer M; Hahn EG
Acta Gastroenterol Belg; 2000; 63(4):366-70. PubMed ID: 11233519
[TBL] [Abstract][Full Text] [Related]
15. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads.
Weng H; Mertens PR; Gressner AM; Dooley S
J Hepatol; 2007 Feb; 46(2):295-303. PubMed ID: 17125875
[TBL] [Abstract][Full Text] [Related]
16. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells.
Wobser H; Dorn C; Weiss TS; Amann T; Bollheimer C; Büttner R; Schölmerich J; Hellerbrand C
Cell Res; 2009 Aug; 19(8):996-1005. PubMed ID: 19546889
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis.
Liu X; Hu H; Yin JQ
Liver Int; 2006 Feb; 26(1):8-22. PubMed ID: 16420505
[TBL] [Abstract][Full Text] [Related]
18. Hepatic fibrosis: from bench to bedside.
Schuppan D; Popov Y
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S300-5. PubMed ID: 12472954
[TBL] [Abstract][Full Text] [Related]
19. Cirrhosis--can we reverse hepatic fibrosis?
Tangkijvanich P; Yee HF
Eur J Surg Suppl; 2002; (587):100-12. PubMed ID: 16144208
[TBL] [Abstract][Full Text] [Related]
20. The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model.
Chen MH; Chen JC; Tsai CC; Wang WC; Chang DC; Tu DG; Hsieh HY
J Ethnopharmacol; 2005 Feb; 97(1):7-13. PubMed ID: 15652268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
